180 related articles for article (PubMed ID: 11003204)
1. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers.
McCaul ME; Wand GS; Rohde C; Lee SM
Alcohol Clin Exp Res; 2000 Sep; 24(9):1385-91. PubMed ID: 11003204
[TBL] [Abstract][Full Text] [Related]
2. 6-beta-naltrexol reduces alcohol consumption in rats.
Rukstalis MR; Stromberg MF; O'Brien CP; Volpicelli JR
Alcohol Clin Exp Res; 2000 Oct; 24(10):1593-6. PubMed ID: 11045869
[TBL] [Abstract][Full Text] [Related]
3. Effects of naltrexone on alcohol self-administration in heavy drinkers.
Davidson D; Palfai T; Bird C; Swift R
Alcohol Clin Exp Res; 1999 Feb; 23(2):195-203. PubMed ID: 10069545
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
[TBL] [Abstract][Full Text] [Related]
5. Naltrexone biotransformation and incidence of subjective side effects: a preliminary study.
King AC; Volpicelli JR; Gunduz M; O'Brien CP; Kreek MJ
Alcohol Clin Exp Res; 1997 Aug; 21(5):906-9. PubMed ID: 9267542
[TBL] [Abstract][Full Text] [Related]
6. Transfer of naltrexone and its metabolite 6,beta-naltrexol into human milk.
Chan CF; Page-Sharp M; Kristensen JH; O'Neil G; Ilett KF
J Hum Lact; 2004 Aug; 20(3):322-6. PubMed ID: 15296587
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
8. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects.
McCaul ME; Wand GS; Eissenberg T; Rohde CA; Cheskin LJ
Neuropsychopharmacology; 2000 May; 22(5):480-92. PubMed ID: 10731623
[TBL] [Abstract][Full Text] [Related]
9. Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol-preferring rats chronically treated with naltrexone.
Zalewska-Kaszubska J; Gorska D; Dyr W; Czarnecka E
Physiol Behav; 2008 Mar; 93(4-5):1005-10. PubMed ID: 18262210
[TBL] [Abstract][Full Text] [Related]
10. Achieving long-term continuous blood naltrexone and 6-beta-naltrexol coverage following sequential naltrexone implants.
Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson RC
Addict Biol; 2004 Mar; 9(1):67-72. PubMed ID: 15203441
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
[TBL] [Abstract][Full Text] [Related]
12. Blood naltrexone and 6-beta-naltrexol levels following naltrexone implant: comparing two naltrexone implants.
Hulse GK; Arnold-Reed DE; O'Neil G; Chan CT; Hansson R; O'Neil P
Addict Biol; 2004 Mar; 9(1):59-65. PubMed ID: 15203440
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
Turncliff RZ; Dunbar JL; Dong Q; Silverman BL; Ehrich EW; Dilzer SC; Lasseter KC
J Clin Pharmacol; 2005 Nov; 45(11):1259-67. PubMed ID: 16239359
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone.
Porter SJ; Somogyi AA; White JM
Addict Biol; 2002 Apr; 7(2):219-25. PubMed ID: 12006217
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of the antagonistic effects of 6 beta-naltrexol and naltrexone against morphine analgesia].
Yan LD; Gong ZH; Yao XJ; Qin BY
Yao Xue Xue Bao; 2003 Aug; 38(8):578-81. PubMed ID: 14628446
[TBL] [Abstract][Full Text] [Related]
16. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.
Brünen S; Bekier NK; Hiemke C; Korf F; Wiedemann K; Jahn H; Kiefer F
Alcohol Alcohol; 2019 Jan; 54(1):51-55. PubMed ID: 30260366
[TBL] [Abstract][Full Text] [Related]
18. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Johnson BA; Ait-Daoud N; Prihoda TJ
Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
[TBL] [Abstract][Full Text] [Related]
19. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
[TBL] [Abstract][Full Text] [Related]
20. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.
Raehal KM; Lowery JJ; Bhamidipati CM; Paolino RM; Blair JR; Wang D; Sadée W; Bilsky EJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):1150-62. PubMed ID: 15716384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
